Compare SkyWest Inc (SKYW) vs Vertex Pharmaceuticals Incorporated (VRTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs Vertex Pharmaceuticals Incorporated — how do they compare? SkyWest Inc trades at $107.91 (market cap $4.18B), while Vertex Pharmaceuticals Incorporated trades at $529.5 (market cap $132.79B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 31.8× SkyWest Inc's market cap, and Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, SkyWest Inc nearer its low. Which is the better fit depends on your goals.
| SKYW | VRTX | |
|---|---|---|
Market Cap | $4.18B | $132.79B |
Sector | Technology | Health |
52-Week High | $123.72 | $529.65 |
52-Week Low | $78.40 | $376.62 |
Enterprise Value | $5.96B | $126.92B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $111.84, down 1.41% on the day, with a bullish technical signal supported by moving averages and a consensus analyst buy rating. Recent Q2 2026 earnings missed estimates at $2.54 EPS versus $2.70 expected, but revenue trends show growth to $4.2B in 2026. The stock benefits from strong profitability with a 9.78% net margin and attractive valuation metrics, including a P/E of 10.69. Key developments include executive stock sales and a 7.7% post-earnings rally noted by Zacks on July 27, 2026.
Outlook remains positive due to undervaluation and fleet expansion, but risks include fuel cost volatility from Iran war impacts (New York Post, July 7, 2026) and insider selling. The consensus price target of $109.33 suggests limited upside, with execution on earnings beats being critical for further gains.
Vertex Pharmaceuticals (VRTX) trades at $496.07, up 2.49% on the day, with a bullish technical signal from moving averages and strong institutional support. The company reported Q2 2026 revenue of $3.3 billion, beating estimates, and raised its full-year sales outlook, driven by cystic fibrosis treatments and newer products like CASGEVY. Financials show robust profitability with a 35% net income margin and positive cash flow trends, though recent EPS results have been mixed.
Outlook remains positive with an 84% analyst buy rating and a $534.25 consensus price target, implying upside. Key risks include execution on new product launches and competitive pressures, but solid fundamentals and raised guidance support a constructive view for investors seeking growth in biopharma.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →
